155 related articles for article (PubMed ID: 8565031)
1. Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study.
Overgaard K; Lindsay R; Christiansen C
Clin Ther; 1995; 17(4):680-5. PubMed ID: 8565031
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
Chesnut CH; Silverman S; Andriano K; Genant H; Gimona A; Harris S; Kiel D; LeBoff M; Maricic M; Miller P; Moniz C; Peacock M; Richardson P; Watts N; Baylink D
Am J Med; 2000 Sep; 109(4):267-76. PubMed ID: 10996576
[TBL] [Abstract][Full Text] [Related]
3. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
4. Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women.
Rizzoli R; Sigaud A; Azria M; Herrmann FR
Osteoporos Int; 2015 Jan; 26(1):383-93. PubMed ID: 25566730
[TBL] [Abstract][Full Text] [Related]
5. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
Binkley N; Bolognese M; Sidorowicz-Bialynicka A; Vally T; Trout R; Miller C; Buben CE; Gilligan JP; Krause DS;
J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
[TBL] [Abstract][Full Text] [Related]
6. Salmon calcitonin in the prevention of bone loss at perimenopause.
Arnala I; Saastamoinen J; Alhava EM
Bone; 1996 Jun; 18(6):629-32. PubMed ID: 8806006
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
Reginster JY; Deroisy R; Lecart MP; Sarlet N; Zegels B; Jupsin I; de Longueville M; Franchimont P
Am J Med; 1995 May; 98(5):452-8. PubMed ID: 7733123
[TBL] [Abstract][Full Text] [Related]
8. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
Adami S; Passeri M; Ortolani S; Broggini M; Carratelli L; Caruso I; Gandolini G; Gnessi L; Laurenzi M; Lombardi A
Bone; 1995 Oct; 17(4):383-90. PubMed ID: 8573412
[TBL] [Abstract][Full Text] [Related]
9. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis].
Agnusdei D; Gonnelli S; Camporeale A; Batignani T; Nardi P; Ianes A; Gennari C
Minerva Endocrinol; 1989; 14(3):169-76. PubMed ID: 2695815
[TBL] [Abstract][Full Text] [Related]
10. Early effect of nasal salmon calcitonin on the bone marker Crosslaps.
Ofluoglu D; Karadag-Saygi E; Canbulat C; Gunduz OH; Kul-Panza E; Akyuz G
Rheumatol Int; 2006 Feb; 26(4):288-91. PubMed ID: 15875189
[TBL] [Abstract][Full Text] [Related]
11. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.
Ellerington MC; Hillard TC; Whitcroft SI; Marsh MS; Lees B; Banks LM; Whitehead MI; Stevenson JC
Calcif Tissue Int; 1996 Jul; 59(1):6-11. PubMed ID: 8661976
[TBL] [Abstract][Full Text] [Related]
12. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis.
Flicker L; Hopper JL; Larkins RG; Lichtenstein M; Buirski G; Wark JD
Osteoporos Int; 1997; 7(1):29-35. PubMed ID: 9102059
[TBL] [Abstract][Full Text] [Related]
13. Effect of different doses of nasal salmon calcitonin on bone mass.
Thamsborg G; Storm TL; Sykulski R; Brinch E; Nielsen HK; Sørensen OH
Calcif Tissue Int; 1991 May; 48(5):302-7. PubMed ID: 2054714
[TBL] [Abstract][Full Text] [Related]
14. Treatment of postmenopausal osteoporosis with salmon calcitonin nasal spray: evaluation by bone mineral content and biochemical patterns.
Tolino A; Romano L; Ronsini S; Riccio S; Montemagno U
Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):358-60. PubMed ID: 8370634
[TBL] [Abstract][Full Text] [Related]
15. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin.
Reginster JY; Denis D; Deroisy R; Lecart MP; De Longueville M; Zegels B; Sarlet N; Noirfalisse P; Franchimont P
J Bone Miner Res; 1994 Jan; 9(1):69-73. PubMed ID: 8154311
[TBL] [Abstract][Full Text] [Related]
16. Nasal calcitonin for treatment of established osteoporosis.
Overgaard K; Riis BJ; Christiansen C; Pødenphant J; Johansen JS
Clin Endocrinol (Oxf); 1989 Apr; 30(4):435-42. PubMed ID: 2688995
[TBL] [Abstract][Full Text] [Related]
17. Salmon calcitonin plus intravaginal estriol: an effective treatment for the menopause.
Melis GB; Cagnacci A; Bruni V; Falsetti L; Jasonni VM; Nappi C; Polatti F; Volpe A
Maturitas; 1996 May; 24(1-2):83-90. PubMed ID: 8794438
[TBL] [Abstract][Full Text] [Related]
18. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study.
Overgaard K
Calcif Tissue Int; 1994 Aug; 55(2):82-6. PubMed ID: 7953984
[TBL] [Abstract][Full Text] [Related]
19. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss.
Gennari C; Agnusdei D; Montagnani M; Gonnelli S; Civitelli R
Calcif Tissue Int; 1992 Apr; 50(4):381-3. PubMed ID: 1571851
[TBL] [Abstract][Full Text] [Related]
20. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis.
Adachi JD; Bensen WG; Bell MJ; Bianchi FA; Cividino AA; Craig GL; Sturtridge WC; Sebaldt RJ; Steele M; Gordon M; Themeles E; Tugwell P; Roberts R; Gent M
Br J Rheumatol; 1997 Feb; 36(2):255-9. PubMed ID: 9133941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
